![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SUNESIS SELECTS DEVELOPMENT CANDIDATE FOR ANTICANCER THERAPY
SUNESIS SELECTS DEVELOPMENT CANDIDATE FOR ANTICANCER THERAPY
August 30, 2005
Sunesis Pharmaceuticals has selected an Aurora kinase development candidate, designated SNS-314, for IND-enabling preclinical development. SNS-314 is a small molecule kinase inhibitor that has shown promising selectivity and activity as a potential anticancer therapy for in vitro and in vivo testing. The company plans to file an investigational new drug (IND) application with the FDA and commence clinical trials for SNS-314 in 2006.
Aurora kinases are overexpressed in a number of tumor types including colon cancer, breast cancer and leukemia. Aurora kinases are key enzymes involved in cell growth and division and play an essential role in the abnormal proliferation of tumor cells. SNS-314 is a targeted inhibitor of Aurora A and B intended to arrest cellular proliferation and limit tumor growth by initiating programmed cell death. SNS-314 has demonstrated the ability to inhibit tumor growth in vivo. In preliminary safety studies, SNS-314 does not cause any unanticipated toxicity when administered either orally or intravenously to mice or rats at therapeutic doses.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct